Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of 惠升 insulin degludec and insulin aspart injection versus Ryzodeg in type 2 diabetes mellitus
CTR20212490Phase 3Active
- Sponsor
- Huisheng Biopharmaceutical
- Start
- Oct 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by Huisheng Biopharmaceutical. Started Oct 2021; status: active.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20212490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212490.